Myosin-Catalyzed ATP Hydrolysis in the Presence of Disease-Causing Mutations: Mavacamten as a Way to Repair Mechanism
The Journal of Physical Chemistry B · 2024
DOI: 10.1021/acs.jpcb.4c01601 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Physical Chemistry B, 2024. Verfasst von Ananya Chakraborti und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721, United States. Hauptthemen laut MEDLINE: Adenosine Triphosphate, Cardiomyopathy, Hypertrophic, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Hypertrophic cardiomyopathy is one of the most common forms of genetic cardiomyopathy. Mavacamten is a first-in-class myosin modulator that was identified via activity screening on the wild type, and it is FDA-approved for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The drug selectively binds to the cardiac β-myosin, inhibiting myosin function to decrease cardiac contractility. Though the drug is thought to affect multiple steps of the myosin cross-bridge cycle, its detailed mechanism of action is still under investigation. Individual steps in the overall cross-bridge cycle must be queried to elucidate the full mechanism of action. In this study, we utilize the rare-event method of transition path sampling to generate reactive trajectories to gain insights into the action of the drug on the dynamics and rate of the ATP hydrolysis step for human cardiac β-myosin. We study three known HCM causative myosin mutations: R453C, P710R, and R712L to observe the effect of the drug on the alterations caused by these mutations in the chemical step. Since the crystal structure of the drug-bound myosin was not available at the time of this work, we created a model of the drug-bound system utilizing a molecular docking approach. We find a significant effect of the drug in one case, where the actual mechanism of the reaction is altered from the wild type by mutation. The drug restores both the rate of hydrolysis to the wildtype level and the mechanism of the reaction. This is a way to check the effect of the drug on untested mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721, United States.
- Department of Biomedical Engineering, University of Arizona, Tucson, Arizona 85724, United States.
ORCID-Profile: Steven D Schwartz
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Chakraborti, A., Tardiff, J. C., & Schwartz, S. D. (2024). Myosin-Catalyzed ATP Hydrolysis in the Presence of Disease-Causing Mutations: Mavacamten as a Way to Repair Mechanism. The Journal of Physical Chemistry B. https://doi.org/10.1021/acs.jpcb.4c01601
Vancouver
Chakraborti A, Tardiff JC, Schwartz SD. Myosin-Catalyzed ATP Hydrolysis in the Presence of Disease-Causing Mutations: Mavacamten as a Way to Repair Mechanism. The Journal of Physical Chemistry B. 2024. doi:10.1021/acs.jpcb.4c01601
BibTeX
@article{Chakraborti2024,
author = {Chakraborti, Ananya and Tardiff, Jil C and Schwartz, Steven D},
title = {Myosin-Catalyzed ATP Hydrolysis in the Presence of Disease-Causing Mutations: Mavacamten as a Way to Repair Mechanism},
journal = {The Journal of Physical Chemistry B},
year = {2024},
doi = {10.1021/acs.jpcb.4c01601}
}
EUVIMED